ES2084347T3 - Derivados de 5-heteroil-indol. - Google Patents

Derivados de 5-heteroil-indol.

Info

Publication number
ES2084347T3
ES2084347T3 ES92904837T ES92904837T ES2084347T3 ES 2084347 T3 ES2084347 T3 ES 2084347T3 ES 92904837 T ES92904837 T ES 92904837T ES 92904837 T ES92904837 T ES 92904837T ES 2084347 T3 ES2084347 T3 ES 2084347T3
Authority
ES
Spain
Prior art keywords
alkyl
hydrogen
heteroil
indol
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92904837T
Other languages
English (en)
Inventor
Jolanta Teresa Nowakowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2084347T3 publication Critical patent/ES2084347T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

COMPUESTOS DE FORMULA (I) DONDE R1 ES HIDROGENO, ALKILO C1-C2, FENILO, BENCILO, -COR4, O SO2R4; R2 ES (1), (2) O (3); R3 ES -(CH2)D-Z; Z ES (4); R4 ES ALKILO C1-C6, FENILO, O BENCILO; R5 ES HIDROGENO O ALKILO C1-C6;R6, R7, R11, R12, Y R13, SON CADA UNO INDEPENDIENTEMENTE HIDROGENO O ALKILO C1-C6, O BIEN R8 O R9 ES HIDROGENO, ALKILO C1-C6, ALKILO C1-C6 SUSTITUIDO POR HALOGENO, 1-PIRROLIDINILMETIL, 1-PIPERIDINILMETIL, CICLOPENTILMETIL, CICLOHEXILMETIL O (5) CON EL OTRO SIENDO EL ENLACE ENTRE R3 Y Z; Q ES (6) O (7).
ES92904837T 1991-02-12 1992-02-03 Derivados de 5-heteroil-indol. Expired - Lifetime ES2084347T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65471291A 1991-02-12 1991-02-12

Publications (1)

Publication Number Publication Date
ES2084347T3 true ES2084347T3 (es) 1996-05-01

Family

ID=24625959

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92904837T Expired - Lifetime ES2084347T3 (es) 1991-02-12 1992-02-03 Derivados de 5-heteroil-indol.

Country Status (24)

Country Link
EP (1) EP0571471B1 (es)
JP (1) JPH07121942B2 (es)
KR (1) KR930703305A (es)
AT (1) ATE135005T1 (es)
AU (1) AU655456B2 (es)
CA (1) CA2101521A1 (es)
CZ (1) CZ165693A3 (es)
DE (1) DE69208868T2 (es)
DK (1) DK0571471T3 (es)
ES (1) ES2084347T3 (es)
FI (1) FI933551L (es)
GR (1) GR3019778T3 (es)
HU (1) HUT65766A (es)
IE (1) IE920442A1 (es)
IL (1) IL100888A0 (es)
MX (1) MX9200569A (es)
MY (1) MY131298A (es)
NO (1) NO932859D0 (es)
NZ (1) NZ241584A (es)
PT (1) PT100114A (es)
TW (1) TW263508B (es)
WO (1) WO1992013856A1 (es)
YU (1) YU13792A (es)
ZA (1) ZA92969B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW288010B (es) * 1992-03-05 1996-10-11 Pfizer
RU2101283C1 (ru) * 1992-04-07 1998-01-10 Пфайзер Инк. Производные индола или их фармацевтически приемлемые соли
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226537D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
ES2070087B1 (es) * 1993-08-13 1996-02-16 Pfizer Derivados de indol
US6423731B2 (en) 1994-01-06 2002-07-23 Zeneca Limited Indole derivatives as prodrugs of 5-HT1-like receptor agonists
US5468768A (en) * 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
EP0759918A1 (en) * 1994-05-19 1997-03-05 MERCK SHARP & DOHME LTD. Piperazine, piperidine and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-ht1d-alpha agonists
PT765322E (pt) * 1994-06-01 2002-01-30 Astrazeneca Ab Derivados indole pro-farmacos de agonistas de receptores tipo 5-ht1
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
CN1184425A (zh) * 1995-03-20 1998-06-10 伊莱利利公司 5－取代－3－(1,2,3,6－四氢吡啶－4－基)－和3－(哌啶－4－基)－1h－吲哚:新型5－ht1f激动剂
JPH11513666A (ja) * 1995-10-10 1999-11-24 イーライ・リリー・アンド・カンパニー Ｎ−［２−置換−３−（２−アミノエチル）−１ｈ−インドール−５−イル］−アミド：新規５−ｈｔ▲下１ｆ▼作動剤
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
FR2763243A1 (fr) * 1997-05-14 1998-11-20 Pf Medicament Utilisation d'amines indoliques comme medicaments antithrombotiques
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
ATE241615T1 (de) * 1998-03-09 2003-06-15 Lundbeck & Co As H 5-heteroaryl-substituierte indole
WO2000000487A1 (en) * 1998-06-30 2000-01-06 Eli Lilly And Company 5-ht1f agonists
ATE375990T1 (de) * 1999-04-21 2007-11-15 Nps Allelix Corp Piperidin-indol derivate mit 5-ht6 affinität
WO2001034146A1 (en) * 1999-11-08 2001-05-17 Smithkline Beecham Corporation Novel anti-infectives
KR100823908B1 (ko) 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-ｎ1-(벤젠술포닐)인돌 및 이의치료 용도
DE10121217A1 (de) * 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
WO2003099206A2 (en) 2002-05-21 2003-12-04 Bristol-Myers Squibb Company Indole compounds useful as impdh inhibitors
EP1581492B1 (en) 2002-11-28 2008-07-16 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
WO2005005439A1 (en) * 2003-07-09 2005-01-20 Suven Life Sciences Limited Benzothiazino indoles
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
WO2005121132A1 (ja) * 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
JP5833804B2 (ja) 2005-04-13 2015-12-16 ニューラクソン，インコーポレーテッド Ｎｏｓ阻害活性を有する置換インドール化合物
KR20080031038A (ko) * 2005-07-29 2008-04-07 4에스체 악티엔게젤샤프트 신규의 헤테로환 ＮＦ-κＢ 억제제
AU2007217040A1 (en) 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
TW200808780A (en) 2006-04-13 2008-02-16 Neuraxon Inc 1,5 and 3,6- substituted indole compounds having NOS inhibitory activity
EP2049481A2 (en) * 2006-08-09 2009-04-22 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
MX356032B (es) 2007-11-16 2018-04-11 Neuraxon Inc Compuestos indola y métodos para tratar el dolor visceral.
JP6063870B2 (ja) * 2010-11-08 2017-01-18 ライセラ・コーポレイション ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
RU2014149136A (ru) 2012-05-08 2016-07-10 Мерк Шарп И Доум Корп. ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
WO2013169864A2 (en) 2012-05-08 2013-11-14 Lycera Corporation TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
MX2016010998A (es) 2014-02-27 2017-03-31 Lycera Corp Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
CA2975997A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
HK1253734A1 (zh) 2015-06-11 2019-06-28 The Regents Of The University Of Michigan 用作RORγ激动剂和用於治疗疾病的芳基二氢-2H-苯并[B][1，4]恶嗪磺酰胺和相关化合物
CA3002850A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof
AU2016344111A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
JP2018531958A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
DE3678805D1 (de) * 1985-11-08 1991-05-23 Glaxo Group Ltd Indolderivate.
GB8600398D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
SI9111010B (sl) * 1990-06-07 2005-02-28 Astrazeneca Ab 3,5-disubstituirani indolni derivati kot "5-HT1-podobni" receptorski agonisti

Also Published As

Publication number Publication date
IL100888A0 (en) 1992-11-15
EP0571471B1 (en) 1996-03-06
IE920442A1 (en) 1992-08-12
GR3019778T3 (en) 1996-07-31
ZA92969B (en) 1993-08-11
YU13792A (sh) 1994-11-15
HU9302328D0 (en) 1993-10-28
DE69208868T2 (de) 1996-10-17
FI933551A0 (fi) 1993-08-11
HUT65766A (en) 1994-07-28
WO1992013856A1 (en) 1992-08-20
JPH06500122A (ja) 1994-01-06
MY131298A (en) 2007-08-30
FI933551A7 (fi) 1993-08-11
AU655456B2 (en) 1994-12-22
NZ241584A (en) 1994-12-22
DK0571471T3 (da) 1996-04-01
KR930703305A (ko) 1993-11-29
AU1263792A (en) 1992-09-07
DE69208868D1 (de) 1996-04-11
NO932859L (no) 1993-08-11
JPH07121942B2 (ja) 1995-12-25
TW263508B (es) 1995-11-21
MX9200569A (es) 1992-08-01
NO932859D0 (no) 1993-08-11
CZ165693A3 (en) 1994-05-18
FI933551L (fi) 1993-08-11
PT100114A (pt) 1993-05-31
CA2101521A1 (en) 1992-08-13
ATE135005T1 (de) 1996-03-15
EP0571471A1 (en) 1993-12-01

Similar Documents

Publication Publication Date Title
ES2084347T3 (es) Derivados de 5-heteroil-indol.
ES8603711A1 (es) Procedimiento para preparar compuestos benzimidazoles 2-piridilmetil-tio y sulfinil substituidos
ES2066991T3 (es) Agentes hipoglucemiantes de oxazolidinadiona.
DE69421824D1 (de) Cyclische fungizide amide
ATE31307T1 (de) Benzofuran- und benzopyrancarboxamid-derivate.
NZ332559A (en) 3-mercapto-propylamine substituted 4-carbonylamino-5,5-dimethyl-thiazolidine derivatives
PL216409A1 (es)
DE69728544D1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
DE69813605D1 (de) Benzofuranderivate
NZ528997A (en) Sulfonamides
DK429089A (da) Alkylbenzylaminer
ES2001106A6 (es) Procedimiento para la obtencion de 1-aril-pirazoles
DK0695755T3 (da) Pyrrolocarbazoler
DK0677042T3 (da) Selektive ligander af 5HT1D-5HT1B-receptorer, der er afledt af indolpiperazin og er nyttige som lægemidler
ES2064618T3 (es) Agonistas de serotonina de tetrahidrobenz(c,d)indol.
FI834730A0 (fi) 1-karboxialkanoylperhydro-indol-2-karboxylsyror och deras derivat
NO902336L (no) Antispasmotiske midler.
PE14896A1 (es) Aminoalcanimidazoles y triazoles acilados
AR247735A1 (es) Sulfonildiamidas sustituidas, procedimientos para su preparacion, intermediarios utilizados en el procedimiento, y su utilizacion como herbicidas y reguladoras del crecimiento de las plantas
PT87048A (pt) Process for preparing benzazepine sulfonamides antiarrhythmic agents
ES2092112T3 (es) Agentes hipoglicemicos de tiazolidindiona.
CO4410332A1 (es) Oxazoles y tiazoles sustituidos
GR1001309B (el) Μεθοδος παρασκευης παραγωγου ενωσεως της διχλωροανιλινης.
DE3662268D1 (de) Subsitued furazans
AR248401A1 (es) Un microbiocida de 3-halo-5-halometil-2-oxazolidinona, su preparacion e intermediario 5-halometil-2-oxazolidinona y control de un microorganismo en un sistema acuoso y sobre una superficie.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 571471

Country of ref document: ES